Focus Partners Advisor Solutions LLC Raises Position in Illumina, Inc. $ILMN

Focus Partners Advisor Solutions LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 46.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,661 shares of the life sciences company’s stock after buying an additional 6,910 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Illumina were worth $2,057,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Illumina in the third quarter valued at $29,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Illumina in the third quarter valued at $33,000. NewSquare Capital LLC grew its holdings in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares in the last quarter. Finally, Mather Group LLC. purchased a new stake in Illumina during the 3rd quarter worth $46,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a report on Monday, January 26th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Stifel Nicolaus upped their target price on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Finally, Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Trading Down 0.5%

NASDAQ:ILMN opened at $128.97 on Thursday. The company has a market cap of $19.72 billion, a PE ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 1.45. The business’s 50 day moving average is $134.74 and its two-hundred day moving average is $118.89. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.